![]() ![]() Their loss will be more informed investors' gain." "Investors alienated from Israel-based companies thanks to deliberately inaccurate media coverage questioning the country's durability are missing out in a major way. "I'm excited to be investing in a company with Oramed's fundamentals and management," Shapiro told ALL ISRAEL NEWS via WhatsApp. ![]() Bloomberg estimated that the shares cost Shapiro around $4.7 million based on regulatory filings published late Monday. ![]() The board determined Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Shapiro's appointment was effective as of May 1. It aims to offer oral delivery solutions for drugs otherwise delivered via injection. Oramed is an American-Israeli clinical-stage pharmaceutical company based on technology developed by Jerusalem's Hadassah-University Medical Center. Ben Shapiro, the founder of the Daily Wire and the host of the Ben Shapiro Show podcast, has joined the board of directors of Oramed Pharmaceuticals and now holds nearly 5% of Oramed's outstanding stock, the company announced.Īccording to Oramed, theirs is the first Israeli company board the conservative star has joined and Bloomberg reports he is also now the company's most significant shareholder. ![]()
0 Comments
Leave a Reply. |